Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.
In this small study, even patients with high-risk tumors appeared to benefit from nephron-sparing surgery.
A phase 2 exploratory study of men with low- and intermediate-risk localized prostate cancer demonstrated the oncologic benefit of enzalutamide treatment vs active surveillance.
Five-year survival rates following nephrectomy for renal cell carcinoma are higher among patients with favorable vs unfavorable histology.
A small randomized trial finds no worse satisfaction with telemedicine vs in-person visits among patients with OAB.
Greater consumption of healthful plant-based foods is associated with significantly reduced risks for advanced, lethal, and fatal prostate cancer, especially among men younger than 65 years.
Investigators report increased risks for adverse pathology and 90-day readmission.
In a single-center study, the median duration of percutaneous tibial nerve stimulation therapy was 147 days.
In addition to similar rates of overall survival, patients undergoing partial and radical cystectomy had comparable rates of upstaging to pT3-4 disease.
Neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma may improve pathologic outcomes regardless of age, new data suggest.
